Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Autoimmune Disorders

  Free Subscription


Articles published in J Neurol

Retrieve available abstracts of 390 articles:
HTML format



Single Articles


    February 2024
  1. OHNARI K, Hashimoto T, Iwanaka Y, Ohnari K, et al
    Dramatic improvement in refractory myasthenia gravis with eculizumab treatment: a case report.
    J Neurol. 2024 Feb 23. doi: 10.1007/s00415-024-12245.
    PubMed    


  2. GREGULETZ P, Plotz M, Baade-Buttner C, Bien CG, et al
    Different pain phenotypes are associated with anti-Caspr2 autoantibodies.
    J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12224.
    PubMed     Abstract available


  3. CUTILLO G, Rubin M, d'Amore G, Malcangi M, et al
    Infratentorial posterior reversible encephalopathy syndrome in INFbeta1a-treated multiple sclerosis patient.
    J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12226.
    PubMed    


  4. BIANCHI A, Matranga D, Patti F, Maniscalco L, et al
    The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT).
    J Neurol. 2024 Feb 16. doi: 10.1007/s00415-024-12214.
    PubMed     Abstract available


  5. HARDING KE, Kreft KL, Ben-Shlomo Y, Robertson NP, et al
    Prodromal multiple sclerosis: considerations and future utility.
    J Neurol. 2024 Feb 11. doi: 10.1007/s00415-023-12173.
    PubMed     Abstract available


  6. VANCURA J, Boyd NK, Vogel BN, Nagesh D, et al
    Rapidly progressive moyamoya vasculopathy stabilized with immunotherapy in aicardi-goutieres syndrome.
    J Neurol. 2024;271:1019-1022.
    PubMed    


    January 2024
  7. BAJRAMI A, Tamanti A, Peloso A, Ziccardi S, et al
    Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.
    J Neurol. 2024 Jan 30. doi: 10.1007/s00415-023-12179.
    PubMed     Abstract available


  8. BOUMAN PM, van Dam MA, Jonkman LE, Steenwijk MD, et al
    Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time.
    J Neurol. 2024 Jan 30. doi: 10.1007/s00415-024-12185.
    PubMed     Abstract available


  9. NAUTA IM, Kessels RPC, Bertens D, Stam CJ, et al
    Neurophysiological brain function predicts response to cognitive rehabilitation and mindfulness in multiple sclerosis: a randomized trial.
    J Neurol. 2024 Jan 26. doi: 10.1007/s00415-024-12183.
    PubMed     Abstract available


  10. CENSI S, Bisaccia G, Gallina S, Tomassini V, et al
    Guillain-Barre syndrome and COVID-19 vaccination: a systematic review and meta-analysis.
    J Neurol. 2024 Jan 17. doi: 10.1007/s00415-024-12186.
    PubMed     Abstract available


  11. FENG G, Posa S, Sureshkumar A, Simpson S, et al
    Experiences of people with multiple sclerosis and clinicians in using cognitive behavioural therapies for hidden symptoms: a systematic review and meta-aggregation.
    J Neurol. 2024 Jan 14. doi: 10.1007/s00415-023-12116.
    PubMed     Abstract available


  12. ZHENG P, Sandroff BM, Motl RW
    Free-living ambulatory physical activity and cognitive function in multiple sclerosis: the significance of step rate vs. step volume.
    J Neurol. 2024 Jan 12. doi: 10.1007/s00415-023-12169.
    PubMed     Abstract available


  13. MAILLART E, Todesco E, Assoumou L, Beigneux Y, et al
    Humoral response after accelerated schedule of HBV vaccination in MS patients before anti-CD20 therapy.
    J Neurol. 2024 Jan 11. doi: 10.1007/s00415-023-12175.
    PubMed    


  14. TRYFONOS C, Chrysafi M, Vadikolias K, Berberoglou L, et al
    Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence.
    J Neurol. 2024 Jan 4. doi: 10.1007/s00415-023-12140.
    PubMed     Abstract available


  15. LOREFICE L, Ferraro OE, Fenu G, Amato MP, et al
    Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.
    J Neurol. 2024 Jan 3. doi: 10.1007/s00415-023-12152.
    PubMed     Abstract available


  16. FAVRUZZO F, Palmieri A, Giopato F, Cardellini D, et al
    Subacute transverse myelitis of possible vasculitic origin after SARS-CoV2 and Varicella-Zoster virus infections: a case report.
    J Neurol. 2024;271:75-78.
    PubMed    


  17. NEUMANN B, Angstwurm K, Dohmen C, Mergenthaler P, et al
    Weaning and extubation failure in myasthenic crisis: a multicenter analysis.
    J Neurol. 2024;271:564-574.
    PubMed     Abstract available


  18. WIESENFARTH M, Stamminger T, Zizer E, Tumani H, et al
    Neurological manifestation of HEV infection: still a rare disease entity?
    J Neurol. 2024;271:386-394.
    PubMed     Abstract available


  19. MOSER T, Zimmermann G, Baumgartner A, Berger T, et al
    Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.
    J Neurol. 2024;271:374-385.
    PubMed     Abstract available


  20. KUMPFEL T, Giglhuber K, Aktas O, Ayzenberg I, et al
    Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
    J Neurol. 2024;271:141-176.
    PubMed     Abstract available


    December 2023
  21. AZZIMONTI M, Margoni M, Zanetta C, Genovese F, et al
    Tumefactive demyelinating lesions: a challenging first manifestation of multiple sclerosis.
    J Neurol. 2023 Dec 28. doi: 10.1007/s00415-023-12164.
    PubMed    


  22. LIU M, Ren H, Wang L, Fan S, et al
    Prognostic and relapsing factors of primary autoimmune cerebellar ataxia: a prospective cohort study.
    J Neurol. 2023 Dec 23. doi: 10.1007/s00415-023-12128.
    PubMed     Abstract available


  23. IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al
    Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.
    J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12137.
    PubMed     Abstract available


  24. ANDORRA M, Freire A, Zubizarreta I, de Rosbo NK, et al
    Predicting disease severity in multiple sclerosis using multimodal data and machine learning.
    J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12132.
    PubMed     Abstract available


  25. MISTRI D, Valsasina P, Storelli L, Filippi M, et al
    Monoaminergic network dysfunction and development of depression in multiple sclerosis: a longitudinal investigation.
    J Neurol. 2023 Dec 19. doi: 10.1007/s00415-023-12138.
    PubMed     Abstract available


  26. HABBESTAD A, Willumsen JS, Aarseth JH, Grytten N, et al
    Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study.
    J Neurol. 2023 Dec 14. doi: 10.1007/s00415-023-12047.
    PubMed     Abstract available


  27. COVEY TJ, Golan D, Sergott R, Wilken J, et al
    Peering further into the mind's eye: combining visual evoked potential and optical coherence tomography measures enhances insight into the variance in cognitive functioning in multiple sclerosis.
    J Neurol. 2023 Dec 13. doi: 10.1007/s00415-023-12075.
    PubMed     Abstract available


  28. ARROYO PEREIRO P, Munoz-Vendrell A, Leon Moreno I, Bau L, et al
    Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
    J Neurol. 2023 Dec 12. doi: 10.1007/s00415-023-12135.
    PubMed     Abstract available


  29. TSAI CC, Jette S, Tremlett H
    Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review.
    J Neurol. 2023 Dec 11. doi: 10.1007/s00415-023-12107.
    PubMed     Abstract available


  30. ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
    The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial.
    J Neurol. 2023 Dec 9. doi: 10.1007/s00415-023-12113.
    PubMed     Abstract available


    November 2023
  31. MEYER-ARNDT L, Brasanac J, Gamradt S, Bellmann-Strobl J, et al
    Body mass, neuro-hormonal stress processing, and disease activity in lean to obese people with multiple sclerosis.
    J Neurol. 2023 Nov 27. doi: 10.1007/s00415-023-12100.
    PubMed     Abstract available


  32. MISTRI D, Tedone N, Biondi D, Vizzino C, et al
    Cognitive phenotypes in multiple sclerosis: mapping the spectrum of impairment.
    J Neurol. 2023 Nov 26. doi: 10.1007/s00415-023-12102.
    PubMed     Abstract available


  33. JAKIMOVSKI D, Kavak KS, Coyle PK, Goodman AD, et al
    Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
    J Neurol. 2023 Nov 23. doi: 10.1007/s00415-023-12099.
    PubMed     Abstract available


  34. BISECCO A, Matrone F, Capobianco M, De Luca G, et al
    COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
    J Neurol. 2023 Nov 20. doi: 10.1007/s00415-023-12084.
    PubMed     Abstract available


  35. SUN Y, Li G, Liu X, Zhao X, et al
    Cerebral glucose hypometabolism and hypoperfusion of cingulate gyrus: an imaging biomarker of autoimmune encephalitis with psychiatric symptoms.
    J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12051.
    PubMed     Abstract available


  36. KENNEDY PGE, George W, Yu X
    The elusive nature of the oligoclonal bands in multiple sclerosis.
    J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12081.
    PubMed     Abstract available


  37. DI FILIPPO M, Ferraro D, Ragonese P, Prosperini L, et al
    SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
    J Neurol. 2023 Nov 3. doi: 10.1007/s00415-023-12034.
    PubMed     Abstract available


  38. FROHLICH K, Mrochen A, Wang R, Haupenthal D, et al
    Cerebral lesions sites in neurosarcoidosis: a lesion mapping study.
    J Neurol. 2023;270:5392-5397.
    PubMed     Abstract available


  39. JEANTIN L, Shor N, Pallix-Guyot M, Roos-Weil D, et al
    Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
    J Neurol. 2023 Nov 1. doi: 10.1007/s00415-023-12055.
    PubMed    


    October 2023
  40. MANTERO V, Cordano C, Balgera R, Basilico P, et al
    Serum sickness in a multiple sclerosis patient treated with ocrelizumab.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12082.
    PubMed    


  41. KAPPOS L, Traboulsee A, Li DKB, Bar-Or A, et al
    Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-11943.
    PubMed     Abstract available


  42. DELGADO SR, Faissner S, Linker RA, Rammohan K, et al
    Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12007.
    PubMed     Abstract available


  43. RIVEL M, Achiron A, Stern Y, Zeilig G, et al
    Emotional burden among MS patients: associations between specific chronic pain diagnoses and psychological features.
    J Neurol. 2023 Oct 24. doi: 10.1007/s00415-023-12048.
    PubMed     Abstract available


  44. ONTANEDA D, Chitnis T, Rammohan K, Obeidat AZ, et al
    Identification and management of subclinical disease activity in early multiple sclerosis: a review.
    J Neurol. 2023 Oct 21. doi: 10.1007/s00415-023-12021.
    PubMed     Abstract available


  45. ZINGANELL A, Gobel G, Berek K, Hofer B, et al
    Multiple sclerosis in the elderly: a retrospective cohort study.
    J Neurol. 2023 Oct 19. doi: 10.1007/s00415-023-12041.
    PubMed     Abstract available


  46. SELMAJ K, Cree BAC, Barnett M, Thompson A, et al
    Multiple sclerosis: time for early treatment with high-efficacy drugs.
    J Neurol. 2023 Oct 18. doi: 10.1007/s00415-023-11969.
    PubMed     Abstract available


  47. RAVANO V, Piredda GF, Krasensky J, Andelova M, et al
    Tract-wise microstructural analysis informs on current and future disability in early multiple sclerosis.
    J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-12023.
    PubMed     Abstract available


  48. MANZANO GS, McEntire C, Venna N
    Case report of palatal tremor as a feature of CASPR2 autoimmune encephalitis.
    J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-11992.
    PubMed    


  49. ZHANG Z, Wang Z, Du X, Huang X, et al
    Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report.
    J Neurol. 2023 Oct 7. doi: 10.1007/s00415-023-12036.
    PubMed    


  50. KRAKER JA, Chen JJ
    An update on optic neuritis.
    J Neurol. 2023;270:5113-5126.
    PubMed     Abstract available


  51. BRISCA G, Marini C, Buratti S, Mariani M, et al
    Acute pediatric encephalitis: etiology, course, and outcome of a 12-year single-center immunocompetent cohort.
    J Neurol. 2023;270:5034-5047.
    PubMed     Abstract available


  52. WANG R, Sun D, Du Q, Shi Z, et al
    Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum disorder with cluster attack: a case report.
    J Neurol. 2023;270:5085-5089.
    PubMed    


    September 2023
  53. RODRIGUEZ DE VERA GOMEZ P, Mendez Muros M, Torres Cuadro A, Toyos Saenz de Miera FJ, et al
    Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.
    J Neurol. 2023 Sep 29. doi: 10.1007/s00415-023-11995.
    PubMed     Abstract available


  54. LI Y, Saul A, Taylor B, Ponsonby AL, et al
    Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
    J Neurol. 2023 Sep 28. doi: 10.1007/s00415-023-11980.
    PubMed     Abstract available


  55. KERNER C, Kotobelli K, Appleby BS, Cohen ML, et al
    Pathological findings in autoimmune encephalitis autopsy specimens from cases of suspected prion disease.
    J Neurol. 2023 Sep 27. doi: 10.1007/s00415-023-12003.
    PubMed     Abstract available


  56. WEEDA MM, van Nederpelt DR, Twisk JWR, Brouwer I, et al
    Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.
    J Neurol. 2023 Sep 17. doi: 10.1007/s00415-023-11937.
    PubMed     Abstract available


  57. FILIPPI M, Grimaldi L, Conte A, Totaro R, et al
    Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
    J Neurol. 2023 Sep 16. doi: 10.1007/s00415-023-11955.
    PubMed     Abstract available


  58. GRIFFITH SP, Wesselingh R, Seery N, Rushen T, et al
    Characterizing cognitive function in patients with autoimmune encephalitis: an Australian prospective study.
    J Neurol. 2023 Sep 14. doi: 10.1007/s00415-023-11967.
    PubMed     Abstract available


  59. MCARTHUR C, Daruwalla C, Jayeskara M, Brown JWL, et al
    Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis.
    J Neurol. 2023 Sep 12. doi: 10.1007/s00415-023-11984.
    PubMed    


  60. DI STEFANO V, Alonge P, Rini N, Militello M, et al
    Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.
    J Neurol. 2023 Sep 8. doi: 10.1007/s00415-023-11970.
    PubMed     Abstract available


  61. JACOBS BM, Tank P, Bestwick JP, Noyce AJ, et al
    Modifiable risk factors for multiple sclerosis have consistent directions of effect across diverse ethnic backgrounds: a nested case-control study in an English population-based cohort.
    J Neurol. 2023 Sep 7. doi: 10.1007/s00415-023-11971.
    PubMed     Abstract available


  62. MCCOMBE JA, Klassen BT, Flanagan EP, Teener JW, et al
    Eculizumab for the treatment of glycine receptor antibody associated stiff-person syndrome.
    J Neurol. 2023;270:4555-4557.
    PubMed    


  63. NAKAMURA N, Ishikawa H, Matsuyama H, Shindo A, et al
    Neuromyelitis optica spectrum disorder with a familial Mediterranean fever gene E84K mutation.
    J Neurol. 2023;270:4529-4532.
    PubMed    


    August 2023
  64. FERRAND M, Epstein J, Soudant M, Guillemin F, et al
    Real-life evaluation of the 2017 McDonald criteria for relapsing-remitting multiple sclerosis after a clinically isolated syndrome confirms a gain in time-to-diagnosis.
    J Neurol. 2023 Aug 31. doi: 10.1007/s00415-023-11905.
    PubMed     Abstract available


  65. BONACCHI R, Valsasina P, Pagani E, Meani A, et al
    Sex-related differences in upper limb motor function in healthy subjects and multiple sclerosis patients: a multiparametric MRI study.
    J Neurol. 2023 Aug 28. doi: 10.1007/s00415-023-11948.
    PubMed     Abstract available


  66. TOSCANO S, Chisari CG, Lo Fermo S, Gulino G, et al
    A dynamic interpretation of kappaFLC index for the diagnosis of multiple sclerosis: a change of perspective.
    J Neurol. 2023 Aug 28. doi: 10.1007/s00415-023-11952.
    PubMed     Abstract available


  67. JAKIMOVSKI D, Zivadinov R, Weinstock Z, Fuchs TA, et al
    Cortical thickness and cognition in older people with multiple sclerosis.
    J Neurol. 2023 Aug 27. doi: 10.1007/s00415-023-11945.
    PubMed     Abstract available


  68. KUDO A, Yaguchi H, Tanaka K, Kimura A, et al
    A retrospective study of autoimmune cerebellar ataxia over a 20-year period in a single institution.
    J Neurol. 2023 Aug 23. doi: 10.1007/s00415-023-11946.
    PubMed     Abstract available


  69. GOERTZEN A, Altawashi AK, Rieck J, Veh RW, et al
    Autoimmune processes in neurological patients are much more common than presently suspected.
    J Neurol. 2023 Aug 21. doi: 10.1007/s00415-023-11901.
    PubMed     Abstract available


  70. CHANSON JB, Bouhour F, Aube-Nathier AC, Mallaret M, et al
    Myasthenia gravis treatment in the elderly presents with a significant iatrogenic risk: a multicentric retrospective study.
    J Neurol. 2023 Aug 17. doi: 10.1007/s00415-023-11925.
    PubMed     Abstract available


  71. SPIERER R, Lavi I, Bloch S, Mazar M, et al
    Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.
    J Neurol. 2023 Aug 17. doi: 10.1007/s00415-023-11935.
    PubMed     Abstract available


  72. KLETENIK I, Cohen AL, Glanz BI, Ferguson MA, et al
    Multiple sclerosis lesions that impair memory map to a connected memory circuit.
    J Neurol. 2023 Aug 2. doi: 10.1007/s00415-023-11907.
    PubMed     Abstract available


  73. AL-ANI A, Chen JJ, Costello F
    Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges.
    J Neurol. 2023;270:4132-4150.
    PubMed     Abstract available


    July 2023
  74. MAHMOOD A, Hawken J, Robertson NP
    Clinical trials in myasthenia gravis.
    J Neurol. 2023 Jul 31. doi: 10.1007/s00415-023-11903.
    PubMed    


  75. QIN M, Chen J, Guo X, Xiang X, et al
    Movement disorders in autoimmune encephalitis: an update.
    J Neurol. 2023 Jul 31. doi: 10.1007/s00415-023-11881.
    PubMed     Abstract available


  76. ROEBEN B, Scharf M, Miske R, Teegen B, et al
    Seroprevalence of autoimmune antibodies in degenerative ataxias: a broad, disease-controlled screening in 456 subjects.
    J Neurol. 2023 Jul 28. doi: 10.1007/s00415-023-11900.
    PubMed    


  77. TILSLEY P, Strohmeyer IA, Heinrich I, Rosenthal F, et al
    Correction to: Physical fitness moderates the association between brain network impairment and both motor function and cognition in progressive multiple sclerosis.
    J Neurol. 2023 Jul 26. doi: 10.1007/s00415-023-11874.
    PubMed    


  78. NOTEBOOM S, van Nederpelt DR, Bajrami A, Moraal B, et al
    Feasibility of detecting atrophy relevant for disability and cognition in multiple sclerosis using 3D-FLAIR.
    J Neurol. 2023 Jul 19. doi: 10.1007/s00415-023-11870.
    PubMed     Abstract available


  79. ROCCA MA, Valsasina P, Lamanna MT, Colombo B, et al
    Functional connectivity modifications in monoaminergic circuits occur in fatigued MS patients treated with fampridine and amantadine.
    J Neurol. 2023 Jul 18. doi: 10.1007/s00415-023-11858.
    PubMed     Abstract available


  80. LOMBARDO-DEL TORO P, Bragado-Trigo I, Arroyo P, Tena-Cucala R, et al
    Fingolimod-associated progressive multifocal leukoencephalopathy in a multiple sclerosis patient with a good response to filgrastim.
    J Neurol. 2023 Jul 17. doi: 10.1007/s00415-023-11865.
    PubMed    


  81. PETROU P, Achiron A, Cohen EG, Garty M, et al
    Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group‏ Viewpoint.
    J Neurol. 2023 Jul 12. doi: 10.1007/s00415-023-11846.
    PubMed     Abstract available


  82. AMATO MP, Bergamaschi R, Centonze D, Mirabella M, et al
    Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study.
    J Neurol. 2023 Jul 5. doi: 10.1007/s00415-023-11820.
    PubMed     Abstract available


  83. NICULAE AS, Niculae LE, Vacaras C, Vacaras V, et al
    Serum levels of neurofilament light chains in pediatric multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2023 Jul 2. doi: 10.1007/s00415-023-11841.
    PubMed     Abstract available


  84. MOOG TM, Smith AD, Burgess KW, McCreary M, et al
    High-efficacy therapies reduce clinical and radiological events more effectively than traditional treatments in neuromyelitis optica spectrum disorder.
    J Neurol. 2023;270:3595-3602.
    PubMed     Abstract available


  85. JARIUS S, Aktas O, Ayzenberg I, Bellmann-Strobl J, et al
    Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
    J Neurol. 2023;270:3341-3368.
    PubMed     Abstract available


  86. LUMSDEN DE, Lim M, Irani S
    Letter to the editors: comment on "Status dystonicus in adult patients with anti-N-methyl-D-asparate-acid receptor encephalitis".
    J Neurol. 2023;270:3630-3631.
    PubMed    


  87. TEZUKA T, Okuzumi S, Nakashima C, Ide T, et al
    Dysautonomia associated with immune checkpoint inhibitors.
    J Neurol. 2023;270:3413-3423.
    PubMed     Abstract available


    June 2023
  88. RUGGIERI S, Prosperini L, Petracca M, Logoteta A, et al
    The added value of spinal cord lesions to disability accrual in multiple sclerosis.
    J Neurol. 2023 Jun 29. doi: 10.1007/s00415-023-11829.
    PubMed     Abstract available


  89. TILSLEY P, Strohmeyer IA, Heinrich I, Rosenthal F, et al
    Physical fitness moderates the association between brain network impairment and both motor function and cognition in progressive multiple sclerosis.
    J Neurol. 2023 Jun 21. doi: 10.1007/s00415-023-11806.
    PubMed     Abstract available


  90. LIANG Y, Wang G, Li B, Li G, et al
    Autoimmune glial fibrillary acidic protein astrocytosis mimicking tuberculous meningitis: a retrospective study.
    J Neurol. 2023 Jun 20. doi: 10.1007/s00415-023-11818.
    PubMed     Abstract available


  91. ROSENSTEIN I, Axelsson M, Novakova L, Malmestrom C, et al
    Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple sclerosis.
    J Neurol. 2023 Jun 14. doi: 10.1007/s00415-023-11817.
    PubMed     Abstract available


  92. KRIEF N, Gabriel R, Cauquil C, Adams D, et al
    Clinical features and maternal and fetal outcomes in women with Guillain-Barre syndrome in pregnancy.
    J Neurol. 2023 Jun 9. doi: 10.1007/s00415-023-11808.
    PubMed     Abstract available


  93. GRANGE E, Solaro C, Di Giovanni R, Marengo D, et al
    The correlation between 9-HPT and patient-reported measures of upper limb function in multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2023 Jun 9. doi: 10.1007/s00415-023-11801.
    PubMed     Abstract available


  94. CHOMPOOPONG P, Rezk M, Mirman I, Berini SE, et al
    TS-HDS autoantibody: clinical characterization and utility from real-world tertiary care center experience.
    J Neurol. 2023 Jun 9. doi: 10.1007/s00415-023-11798.
    PubMed     Abstract available


  95. MONSCHEIN T, Dekany S, Zrzavy T, Ponleitner M, et al
    Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
    J Neurol. 2023 Jun 5. doi: 10.1007/s00415-023-11784.
    PubMed    


  96. HTET ZM, Tallantyre E
    Optic neuritis and MOGAD.
    J Neurol. 2023;270:3278-3279.
    PubMed    


  97. HOLTZER R, Choi J, Motl RW, Foley FW, et al
    Individual reserve in aging and neurological disease.
    J Neurol. 2023;270:3179-3191.
    PubMed     Abstract available


  98. YIN Z, Qiu Y, Duan A, Fang T, et al
    Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
    J Neurol. 2023;270:2950-2963.
    PubMed     Abstract available


  99. ROSSI S, Gelsomino F, Rinaldi R, Muccioli L, et al
    Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
    J Neurol. 2023;270:2975-2986.
    PubMed     Abstract available


    May 2023
  100. LOUAPRE C, Rosenzwajg M, Golse M, Roux A, et al
    A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.
    J Neurol. 2023 May 28. doi: 10.1007/s00415-023-11690.
    PubMed     Abstract available


  101. AZZIMONTI M, Preziosa P, Pagani E, Valsasina P, et al
    Functional and structural brain MRI changes associated with cognitive worsening in multiple sclerosis: a 3-year longitudinal study.
    J Neurol. 2023 May 18. doi: 10.1007/s00415-023-11778.
    PubMed     Abstract available


  102. ZANETTA C, Rocca MA, Meani A, Martinelli V, et al
    Correction to: Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
    J Neurol. 2023 May 17. doi: 10.1007/s00415-023-11772.
    PubMed    


  103. LIU B, Hu J, Sun C, Qiao K, et al
    Effectiveness and safety of rituximab in autoimmune nodopathy: a single-center cohort study.
    J Neurol. 2023 May 17. doi: 10.1007/s00415-023-11759.
    PubMed     Abstract available


  104. MUNOZ-VENDRELL A, Arroyo-Pereiro P, Leon I, Bau L, et al
    Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment.
    J Neurol. 2023;270:2559-2566.
    PubMed     Abstract available


  105. ZHANG Y, Cui L, Chen W, Huang H, et al
    Status dystonicus in adult patients with anti-N-methyl-D-aspartate-acid receptor encephalitis.
    J Neurol. 2023;270:2693-2701.
    PubMed     Abstract available


  106. DENG Z, Wang H, Huang K, Li Y, et al
    Association between vascular risk factors and idiopathic normal pressure hydrocephalus: a Mendelian randomization study.
    J Neurol. 2023;270:2724-2733.
    PubMed     Abstract available


    April 2023
  107. VARLEY JA, Strippel C, Handel A, Irani SR, et al
    Autoimmune encephalitis: recent clinical and biological advances.
    J Neurol. 2023 Apr 28. doi: 10.1007/s00415-023-11685.
    PubMed     Abstract available


  108. VOGRIG A, Versace S, Gigli GL, Fabris M, et al
    Eating reflex epilepsy of presumed autoimmune etiology after SARS-CoV-2 vaccination.
    J Neurol. 2023 Apr 28:1-5. doi: 10.1007/s00415-023-11723.
    PubMed    


  109. KREMMYDA O, Feil K, Bardins S, Strupp M, et al
    Acetyl-DL-leucine in combination with memantine improves acquired pendular nystagmus caused by multiple sclerosis: a case report.
    J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11730.
    PubMed    


  110. MEISEL A, Annane D, Vu T, Mantegazza R, et al
    Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
    J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11699.
    PubMed     Abstract available


  111. VAN DAM M, de Jong BA, Willemse EAJ, Nauta IM, et al
    A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort.
    J Neurol. 2023 Apr 27. doi: 10.1007/s00415-023-11676.
    PubMed     Abstract available


  112. GILHUS NE
    Myasthenia gravis, respiratory function, and respiratory tract disease.
    J Neurol. 2023 Apr 26:1-12. doi: 10.1007/s00415-023-11733.
    PubMed     Abstract available


  113. MARGONI M, Pagani E, Preziosa P, Gueye M, et al
    Unraveling the heterogeneous pathological substrates of relapse-onset multiple sclerosis: a multiparametric voxel-wise 3 T MRI study.
    J Neurol. 2023 Apr 24. doi: 10.1007/s00415-023-11736.
    PubMed     Abstract available


  114. KOUTSOURAKI E, Theodoros K, Eleni G, Marianna K, et al
    Autonomic nervous system disorders in multiple sclerosis.
    J Neurol. 2023 Apr 21. doi: 10.1007/s00415-023-11725.
    PubMed     Abstract available


  115. MONSCHEIN T, Dekany S, Zrzavy T, Ponleitner M, et al
    Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
    J Neurol. 2023 Apr 19. doi: 10.1007/s00415-023-11686.
    PubMed     Abstract available


  116. GANAPATHY SUBRAMANIAN R, Zivadinov R, Bergsland N, Dwyer MG, et al
    Multiple sclerosis optic neuritis and trans-synaptic pathology on cortical thinning in people with multiple sclerosis.
    J Neurol. 2023 Apr 17. doi: 10.1007/s00415-023-11709.
    PubMed     Abstract available


  117. GADOTH A, Devine MF, Pittock SJ, McKeon A, et al
    Sleep disturbances associated with DPPX autoantibodies: a case series.
    J Neurol. 2023 Apr 7. doi: 10.1007/s00415-023-11698.
    PubMed     Abstract available


  118. YEO T, Siew RWE, Gulam MY, Tye JSN, et al
    COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore.
    J Neurol. 2023 Apr 7:1-9. doi: 10.1007/s00415-023-11692.
    PubMed     Abstract available


  119. ZANETTA C, Rocca MA, Meani A, Martinelli V, et al
    Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
    J Neurol. 2023 Apr 7:1-12. doi: 10.1007/s00415-023-11700.
    PubMed     Abstract available


  120. VRENKEN H, Battaglini M, de Vos ML, Nagtegaal GJ, et al
    Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon beta-1a.
    J Neurol. 2023;270:2271-2282.
    PubMed     Abstract available


  121. LEHTO J, Sucksdorff M, Nylund M, Raitanen R, et al
    PET-measurable innate immune cell activation reduction in chronic active lesions in PPMS brain after rituximab treatment: a case report.
    J Neurol. 2023;270:2329-2332.
    PubMed     Abstract available


  122. GHOLIZADEH S, Exuzides A, Lewis KE, Palmer C, et al
    Clinical and epidemiological correlates of treatment change in patients with NMOSD: insights from the CIRCLES cohort.
    J Neurol. 2023;270:2048-2058.
    PubMed     Abstract available


  123. ASTBURY L, Kalra S, Tanasescu R, Constantinescu CS, et al
    CSF lymphocytic pleocytosis does not predict a less favourable long-term prognosis in MS.
    J Neurol. 2023;270:2042-2047.
    PubMed     Abstract available


  124. HIEKE A, Spenner M, Schmitz F, Schumacher A, et al
    The impact of the SARS-CoV-2-pandemic on patients with chronic inflammatory neuropathies: results from the German INHIBIT register.
    J Neurol. 2023;270:1815-1822.
    PubMed     Abstract available


  125. NEHME A, Lanthier S, Boulanger M, Aouba A, et al
    Diagnosis and management of adult primary angiitis of the central nervous system: an international survey on current practices.
    J Neurol. 2023;270:1989-1998.
    PubMed     Abstract available


    March 2023
  126. PLESS S, Woelfle T, Naegelin Y, Lorscheider J, et al
    Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study.
    J Neurol. 2023 Mar 23. doi: 10.1007/s00415-023-11671.
    PubMed     Abstract available


  127. TORRES P, Sancho-Saldana A, Gil Sanchez A, Peralta S, et al
    A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
    J Neurol. 2023 Mar 18:1-12. doi: 10.1007/s00415-023-11575.
    PubMed     Abstract available


  128. ROMANO F, Motl RW, Valsasina P, Amato MP, et al
    Abnormal thalamic functional connectivity correlates with cardiorespiratory fitness and physical activity in progressive multiple sclerosis.
    J Neurol. 2023 Mar 18. doi: 10.1007/s00415-023-11664.
    PubMed     Abstract available


  129. DE ROSA AP, Esposito F, Valsasina P, d'Ambrosio A, et al
    Correction to: Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative.
    J Neurol. 2023 Mar 13. doi: 10.1007/s00415-023-11646.
    PubMed    


  130. MOGAVERO MP, Lanza G, Bruni O, DelRosso LM, et al
    Sleep counts! Role and impact of sleep in the multimodal management of multiple sclerosis.
    J Neurol. 2023 Mar 11. doi: 10.1007/s00415-023-11655.
    PubMed     Abstract available


  131. VU T, Ortiz S, Katsuno M, Annane D, et al
    Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.
    J Neurol. 2023 Mar 9. doi: 10.1007/s00415-023-11617.
    PubMed     Abstract available


  132. VELDKAMP R, D'hooge M, Sandroff BM, DeLuca J, et al
    Profiling cognitive-motor interference in a large sample of persons with progressive multiple sclerosis and impaired processing speed: results from the CogEx study.
    J Neurol. 2023 Mar 7. doi: 10.1007/s00415-023-11636.
    PubMed     Abstract available


  133. LI G, You Q, Hou X, Zhang S, et al
    The effect of exercise on cognitive function in people with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
    J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11649.
    PubMed     Abstract available


  134. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria.
    J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11644.
    PubMed     Abstract available


  135. BARLETTA VT, Herranz E, Treaba CA, Mehndiratta A, et al
    In vivo characterization of microglia and myelin relation in multiple sclerosis by combined (11)C-PBR28 PET and synthetic MRI.
    J Neurol. 2023 Mar 2. doi: 10.1007/s00415-023-11621.
    PubMed     Abstract available


  136. TAKAI K, Endo T, Seki T, Inoue T, et al
    Congestive myelopathy due to craniocervical junction arteriovenous fistulas mimicking transverse myelitis: a multicenter study on 27 cases.
    J Neurol. 2023;270:1745-1753.
    PubMed     Abstract available


  137. VABANESI M, Pinto AL, Vogrig A, Goncalves D, et al
    SOX1 antibody-related paraneoplastic neurological syndromes: clinical correlates and assessment of laboratory diagnostic techniques.
    J Neurol. 2023;270:1691-1701.
    PubMed     Abstract available


  138. DIETMANN AS, Kruse N, Stork L, Gloth M, et al
    Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological-serological correlative study.
    J Neurol. 2023;270:1416-1429.
    PubMed     Abstract available


  139. NGUYEN TT, Kang JJ, Chae JH, Lee E, et al
    Oculomotor fatigability with decrements of saccade and smooth pursuit for diagnosis of myasthenia gravis.
    J Neurol. 2023 Mar 1. doi: 10.1007/s00415-023-11611.
    PubMed     Abstract available


  140. SCHEGK E, Beiser I, Achtnichts L, Nedeltchev K, et al
    Untreated anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia progressing over 27 years.
    J Neurol. 2023 Mar 1. doi: 10.1007/s00415-023-11632.
    PubMed    


    February 2023
  141. BAETGE SJ, Filser M, Renner A, Raithel LM, et al
    Supporting brain health in multiple sclerosis: exploring the potential of neuroeducation combined with practical mindfulness exercises in the management of neuropsychological symptoms.
    J Neurol. 2023 Feb 25:1-14. doi: 10.1007/s00415-023-11616.
    PubMed     Abstract available


  142. MONTINI F, Nozzolillo A, Rancoita PMV, Zanetta C, et al
    Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case-control study.
    J Neurol. 2023 Feb 16:1-8. doi: 10.1007/s00415-023-11618.
    PubMed     Abstract available


  143. DIXON L, Colquhoun M, Taylor E, Carlucci F, et al
    Orbital giant cell arteritis: two cases of bilateral orbital inflammation and arterial diffusion restriction on MRI.
    J Neurol. 2023 Feb 11. doi: 10.1007/s00415-023-11593.
    PubMed    


  144. SWINNEN S, De Wit D, Van Cleemput L, Cassiman C, et al
    Optical coherence tomography as a prognostic tool for disability progression in MS: a systematic review.
    J Neurol. 2023;270:1178-1186.
    PubMed     Abstract available


  145. HUANG L, Wang Y, Zhang R
    Retina thickness in clinically affected and unaffected eyes in patients with aquaporin-4 immunoglobulin G antibody seropositive neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.
    J Neurol. 2023;270:759-768.
    PubMed     Abstract available


  146. FIONDA L, Lauletta A, Leonardi L, Perez JA, et al
    Muscle MRI in immune-mediated necrotizing myopathy (IMNM): implications for clinical management and treatment strategies.
    J Neurol. 2023;270:960-974.
    PubMed     Abstract available


  147. GERNERT JA, Wicklein R, Hemmer B, Kumpfel T, et al
    Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD).
    J Neurol. 2023;270:1135-1140.
    PubMed     Abstract available


  148. MAGRO G, Barone S, Tosto F, De Martino A, et al
    Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic.
    J Neurol. 2023;270:595-600.
    PubMed     Abstract available


    January 2023
  149. MINAMINO M, Miyamoto K, Kuwahara M, Yoshikawa K, et al
    Characteristics of Guillain-Barre syndrome in super-elderly individuals.
    J Neurol. 2023 Jan 16. doi: 10.1007/s00415-023-11567.
    PubMed     Abstract available


  150. CAGOL A, Fuertes NC, Stoessel M, Barakovic M, et al
    Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis.
    J Neurol. 2023 Jan 10. doi: 10.1007/s00415-022-11535.
    PubMed     Abstract available


  151. SACCA F, Barnett C, Vu T, Peric S, et al
    Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT).
    J Neurol. 2023 Jan 4. doi: 10.1007/s00415-022-11517.
    PubMed     Abstract available


  152. LEE SU, Baek SH, Kim HJ, Choi JY, et al
    Acute comitant strabismus in anti-GQ1b antibody syndrome.
    J Neurol. 2023;270:486-492.
    PubMed     Abstract available


  153. HAGEBOUTROS K, Hattiangadi Thomas N, Hutchinson M, Banwell B, et al
    Neuropsychological functioning in children and adolescents with anti-NMDA receptor encephalitis (anti-NMDARE).
    J Neurol. 2023;270:402-412.
    PubMed     Abstract available


  154. YANG S, Zhang C, Zhang TX, Feng B, et al
    A real-world study of interleukin-6 receptor blockade in patients with neuromyelitis optica spectrum disorder.
    J Neurol. 2023;270:348-356.
    PubMed     Abstract available


  155. DAVION JB, Jougleux C, Lopes R, Leclerc X, et al
    Relation between retina, cognition and brain volumes in MS: a consequence of asymptomatic optic nerve lesions.
    J Neurol. 2023;270:240-249.
    PubMed     Abstract available


    December 2022
  156. BARBAGALLO M, Straumann D, Binaghi E, Schmick A, et al
    A rare case of a wall-eyed bilateral internuclear ophthalmoplegia (WEBINO) syndrome in a patient with cutaneous lupus erythematosus after COVID-19 infection.
    J Neurol. 2022 Dec 28:1-5. doi: 10.1007/s00415-022-11548.
    PubMed    


  157. PENNINGTON P, Weinstock-Guttman B, Kolb C, Jakimovski D, et al
    Correction to: Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
    J Neurol. 2022 Dec 27. doi: 10.1007/s00415-022-11540.
    PubMed    


  158. TIERNEY P, Zekeridou A, Adam O
    Phosphodiesterase 10A autoimmunity presenting as cerebellar ataxia responsive to plasma exchange: a case report.
    J Neurol. 2022 Dec 26. doi: 10.1007/s00415-022-11542.
    PubMed    


  159. LOONSTRA FC, Falize KF, de Ruiter LRJ, Schoonheim MM, et al
    Adipokines in multiple sclerosis patients are related to clinical and radiological measures.
    J Neurol. 2022 Dec 23. doi: 10.1007/s00415-022-11519.
    PubMed     Abstract available


  160. SEN MK, Hossain MJ, Mahns DA, Brew BJ, et al
    Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis.
    J Neurol. 2022 Dec 15. doi: 10.1007/s00415-022-11507.
    PubMed     Abstract available


  161. ALBERGONI M, Storelli L, Preziosa P, Rocca MA, et al
    The insula modulates the effects of aerobic training on cardiovascular function and ambulation in multiple sclerosis.
    J Neurol. 2022 Dec 12:1-10. doi: 10.1007/s00415-022-11513.
    PubMed     Abstract available


  162. GANZETTI M, Graves JS, Holm SP, Dondelinger F, et al
    Neural correlates of digital measures shown by structural MRI: a post-hoc analysis of a smartphone-based remote assessment feasibility study in multiple sclerosis.
    J Neurol. 2022 Dec 5. doi: 10.1007/s00415-022-11494.
    PubMed     Abstract available


  163. MOCCIA M, Affinito G, Berera G, Marrazzo G, et al
    Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy.
    J Neurol. 2022;269:6504-6511.
    PubMed     Abstract available


  164. PAKEERATHAN T, Havla J, Schwake C, Salmen A, et al
    Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode.
    J Neurol. 2022;269:6366-6376.
    PubMed     Abstract available


    November 2022
  165. SIMPSON R, Posa S, Bruno T, Simpson S, et al
    Conceptualization, use, and outcomes associated with compassion in the care of people with multiple sclerosis: a scoping review.
    J Neurol. 2022 Nov 29. doi: 10.1007/s00415-022-11497.
    PubMed     Abstract available


  166. PREZIOSA P, Rocca MA, Pagani E, Valsasina P, et al
    Structural and functional magnetic resonance imaging correlates of fatigue and dual-task performance in progressive multiple sclerosis.
    J Neurol. 2022 Nov 27. doi: 10.1007/s00415-022-11486.
    PubMed     Abstract available


  167. FILIPPI M, Preziosa P, Arnold DL, Barkhof F, et al
    Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective.
    J Neurol. 2022 Nov 24. doi: 10.1007/s00415-022-11488.
    PubMed     Abstract available


  168. MIRMOSAYYEB O, Zivadinov R, Weinstock-Guttman B, Benedict RHB, et al
    Optical coherence tomography (OCT) measurements and cognitive performance in multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2022 Nov 17. pii: 10.1007/s00415-022-11449.
    PubMed     Abstract available


  169. KWON YN, Woodhall M, Sung JJ, Kim KK, et al
    Clinical pitfalls and serological diagnostics of MuSK myasthenia gravis.
    J Neurol. 2022 Nov 17. pii: 10.1007/s00415-022-11458.
    PubMed     Abstract available


  170. KIM S, Kim KH, Chung HY, Park HJ, et al
    Anti-titin antibodies are associated with myocarditis in patients with myasthenia gravis.
    J Neurol. 2022 Nov 16. pii: 10.1007/s00415-022-11485.
    PubMed     Abstract available


  171. PENNINGTON P, Weinstock-Guttman B, Kolb C, Jakimovski D, et al
    Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
    J Neurol. 2022 Nov 14. pii: 10.1007/s00415-022-11405.
    PubMed     Abstract available


  172. GALPERIN I, Mirelman A, Schmitz-Hubsch T, Hsieh KL, et al
    Treadmill training with virtual reality to enhance gait and cognitive function among people with multiple sclerosis: a randomized controlled trial.
    J Neurol. 2022 Nov 11. pii: 10.1007/s00415-022-11469.
    PubMed     Abstract available


  173. DE ROSA AP, Esposito F, Valsasina P, d'Ambrosio A, et al
    Resting-state functional MRI in multicenter studies on multiple sclerosis: a report on raw data quality and functional connectivity features from the Italian Neuroimaging Network Initiative.
    J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11479.
    PubMed     Abstract available


  174. SIMPSON R, Posa S, Langer L, Bruno T, et al
    A systematic review and meta-analysis exploring the efficacy of mindfulness-based interventions on quality of life in people with multiple sclerosis.
    J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11451.
    PubMed     Abstract available


  175. TERESHKO Y, Gigli GL, Pez S, De Pellegrin A, et al
    New-onset Myasthenia Gravis after SARS-CoV-2 infection: case report and literature review.
    J Neurol. 2022 Nov 9. pii: 10.1007/s00415-022-11472.
    PubMed     Abstract available


  176. NIINO M, Fukumoto S, Okuno T, Sanjo N, et al
    Health-related quality of life in Japanese patients with multiple sclerosis.
    J Neurol. 2022 Nov 5. pii: 10.1007/s00415-022-11453.
    PubMed     Abstract available


  177. KURI A, Vickaryous N, Awad A, Jacobs BM, et al
    Vitamin D genetic risk scores in multiple sclerosis.
    J Neurol. 2022 Nov 5. pii: 10.1007/s00415-022-11466.
    PubMed     Abstract available


  178. JARIUS S, Haas J, Wildemann B
    Rho GTPase-activating protein 17 (ARHGAP17) as additional autoimmune target in ARHGAP26-IgG/anti-Ca autoantibody-associated autoimmune encephalitis.
    J Neurol. 2022 Nov 4. pii: 10.1007/s00415-022-11417.
    PubMed    


  179. STRANO CMM, Sorrenti B, Bosco L, Falzone YM, et al
    Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report.
    J Neurol. 2022;269:6152-6154.
    PubMed    


    October 2022
  180. OMARY R, Bockisch CJ, De Vere-Tyndall A, Pazahr S, et al
    Lesion follows function: video-oculography compared with MRI to diagnose internuclear ophthalmoplegia in patients with multiple sclerosis.
    J Neurol. 2022 Oct 31. pii: 10.1007/s00415-022-11428.
    PubMed     Abstract available


  181. WUSCHEK A, Bussas M, El Husseini M, Harabacz L, et al
    Somatosensory evoked potentials and magnetic resonance imaging of the central nervous system in early multiple sclerosis.
    J Neurol. 2022 Oct 7. pii: 10.1007/s00415-022-11407.
    PubMed     Abstract available


  182. PREZIOSA P, Pagani E, Meani A, Marchesi O, et al
    NODDI, diffusion tensor microstructural abnormalities and atrophy of brain white matter and gray matter contribute to cognitive impairment in multiple sclerosis.
    J Neurol. 2022 Oct 6. pii: 10.1007/s00415-022-11415.
    PubMed     Abstract available


  183. COSTELLO F, Burton JM
    Contemporary management challenges in seropositive NMOSD.
    J Neurol. 2022;269:5674-5681.
    PubMed     Abstract available


  184. KANG L, Wan C
    Paraneoplastic syndrome in neuroophthalmology.
    J Neurol. 2022;269:5272-5282.
    PubMed     Abstract available


  185. LEVI-STRAUSS J, Provost C, Wane N, Jacquemont T, et al
    NMOSD typical brain lesions after COVID-19 mRNA vaccination.
    J Neurol. 2022;269:5213-5215.
    PubMed    


  186. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset.
    J Neurol. 2022;269:5319-5327.
    PubMed     Abstract available


    September 2022
  187. ZHANG S, Yang S, Lu J, Liu S, et al
    CIDP-like autoimmune nodopathy complicated with focal segmental glomerulosclerosis: a case study and literature review.
    J Neurol. 2022 Sep 30. pii: 10.1007/s00415-022-11369.
    PubMed     Abstract available


  188. STASCHEIT F, Grittner U, Hoffmann S, Mergenthaler P, et al
    Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis.
    J Neurol. 2022 Sep 27. pii: 10.1007/s00415-022-11389.
    PubMed     Abstract available


  189. MARGONI M, Pagani E, Preziosa P, Palombo M, et al
    In vivo quantification of brain soma and neurite density abnormalities in multiple sclerosis.
    J Neurol. 2022 Sep 24. pii: 10.1007/s00415-022-11386.
    PubMed     Abstract available


  190. PAGANI E, Storelli L, Pantano P, Petsas N, et al
    Multicenter data harmonization for regional brain atrophy and application in multiple sclerosis.
    J Neurol. 2022 Sep 24. pii: 10.1007/s00415-022-11387.
    PubMed     Abstract available


  191. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
    Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
    J Neurol. 2022 Sep 22. pii: 10.1007/s00415-022-11385.
    PubMed    


  192. FILSER M, Buchner A, Fink GR, Gold SM, et al
    The manifestation of affective symptoms in multiple sclerosis and discussion of the currently available diagnostic assessment tools.
    J Neurol. 2022 Sep 21. pii: 10.1007/s00415-022-11359.
    PubMed     Abstract available


  193. CHAPPUIS M, Rousseau C, Bajeux E, Wiertlewski S, et al
    Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis.
    J Neurol. 2022 Sep 16. pii: 10.1007/s00415-022-11341.
    PubMed     Abstract available


  194. REYES-VEGA MF, Soto-Cabezas MG, Soriano-Moreno AN, Valle-Campos A, et al
    Clinical features of Guillain-Barre syndrome and factors associated with mortality during the 2019 outbreak in Peru.
    J Neurol. 2022 Sep 13. pii: 10.1007/s00415-022-11331.
    PubMed     Abstract available


  195. NICOLAS P, Marion-Moffet H, Gossez M, Vukusic S, et al
    Anti-SARS-CoV-2 humoral and cellular responses in multiple sclerosis patients treated with anti-CD20 monoclonal antibodies.
    J Neurol. 2022 Sep 12. pii: 10.1007/s00415-022-11353.
    PubMed    


  196. MAIER A, Kapfenberger R, Katona I, Weis J, et al
    Nonregional small fibre neuropathy in cases of autoimmune autonomic neuropathy.
    J Neurol. 2022 Sep 9. pii: 10.1007/s00415-022-11340.
    PubMed     Abstract available


  197. CAPASSO N, Palladino R, Cerbone V, Spiezia AL, et al
    Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study.
    J Neurol. 2022 Sep 1. pii: 10.1007/s00415-022-11350.
    PubMed     Abstract available


    August 2022
  198. WOELFLE T, Pless S, Reyes O, Wiencierz A, et al
    Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study.
    J Neurol. 2022 Aug 30. pii: 10.1007/s00415-022-11306.
    PubMed     Abstract available


  199. GUEGUEN A, Hijazi B, Zuber K, Deschamps R, et al
    Generalization of ocular myasthenia gravis 10 years after onset.
    J Neurol. 2022 Aug 24. pii: 10.1007/s00415-022-11316.
    PubMed     Abstract available


  200. BARNAY M, Duval F, Sole G, Carla L, et al
    Usefulness of subcutaneous immunoglobulin therapy in the management of myasthenia gravis: a retrospective cohort study.
    J Neurol. 2022 Aug 22. pii: 10.1007/s00415-022-11345.
    PubMed     Abstract available


  201. LEHNERER S, Jacobi J, Schilling R, Grittner U, et al
    Correction to: Burden of disease in myasthenia gravis: taking the patient's perspective.
    J Neurol. 2022 Aug 12. pii: 10.1007/s00415-022-11290.
    PubMed    


  202. JAFARPOUR S, Banerjee A, Boyd NK, Vogel BN, et al
    Association of rare variants in genes of immune regulation with pediatric autoimmune CNS diseases.
    J Neurol. 2022 Aug 12. pii: 10.1007/s00415-022-11325.
    PubMed     Abstract available


  203. FEINSTEIN A, Amato MP, Brichetto G, Chataway J, et al
    The late onset of emotional distress in people with progressive multiple sclerosis during the Covid-19 pandemic: longitudinal findings from the CogEx study.
    J Neurol. 2022 Aug 8. pii: 10.1007/s00415-022-11295.
    PubMed     Abstract available


  204. KREFT KL, Robertson NP
    Innovative biomarkers to predict unfavourable outcomes after initiating multiple sclerosis treatment.
    J Neurol. 2022 Aug 1. pii: 10.1007/s00415-022-11300.
    PubMed    


    July 2022
  205. DORON A, Piura Y, Vigiser I, Kolb H, et al
    BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves.
    J Neurol. 2022 Jul 30. pii: 10.1007/s00415-022-11303.
    PubMed     Abstract available


  206. CAPUANO R, Altieri M, Conte M, Bisecco A, et al
    Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod.
    J Neurol. 2022 Jul 26. pii: 10.1007/s00415-022-11296.
    PubMed     Abstract available


  207. BLACKMAN G, Lim MF, Pollak T, Al-Diwani A, et al
    The clinical relevance of serum versus CSF NMDAR autoantibodies associated exclusively with psychiatric features: a systematic review and meta-analysis of individual patient data.
    J Neurol. 2022 Jul 5. pii: 10.1007/s00415-022-11224.
    PubMed     Abstract available


  208. MUNOZ-JURADO A, Escribano BM, Aguera E, Caballero-Villarraso J, et al
    SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.
    J Neurol. 2022 Jul 5. pii: 10.1007/s00415-022-11237.
    PubMed     Abstract available


  209. TAN X, Liu Y, Wu X, Guo Y, et al
    Guillain-Barre-like syndrome: an uncommon feature of CASPR2 and LGI1 autoimmunity.
    J Neurol. 2022 Jul 3. pii: 10.1007/s00415-022-11248.
    PubMed     Abstract available


  210. EID K, Torkildsen O, Aarseth J, Celius EG, et al
    Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy.
    J Neurol. 2022 Jul 3. pii: 10.1007/s00415-022-11249.
    PubMed     Abstract available


  211. MERGENTHALER P, Stetefeld HR, Dohmen C, Kohler S, et al
    Seronegative myasthenic crisis: a multicenter analysis.
    J Neurol. 2022;269:3904-3911.
    PubMed     Abstract available


  212. ALCALA C, Cubas L, Carratala S, Gascon F, et al
    NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.
    J Neurol. 2022;269:3495-3500.
    PubMed     Abstract available


    June 2022
  213. CANNIZZARO M, Ferre L, Clarelli F, Giordano A, et al
    Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients.
    J Neurol. 2022 Jun 27. pii: 10.1007/s00415-022-11227.
    PubMed     Abstract available


  214. SOROSINA M, Barizzone N, Clarelli F, Anand S, et al
    Correction to: A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.
    J Neurol. 2022 Jun 25. pii: 10.1007/s00415-022-11216.
    PubMed    


  215. LEGUY S, Lefort M, Lescot L, Michaud A, et al
    COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients.
    J Neurol. 2022 Jun 23. pii: 10.1007/s00415-022-11215.
    PubMed     Abstract available


  216. SANDROFF BM, Motl RW, Roman CAF, Wylie GR, et al
    Thalamic atrophy moderates associations among aerobic fitness, cognitive processing speed, and walking endurance in persons with multiple sclerosis.
    J Neurol. 2022 Jun 19. pii: 10.1007/s00415-022-11205.
    PubMed     Abstract available


  217. DORCET G, Migne H, Biotti D, Bost C, et al
    Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression.
    J Neurol. 2022 Jun 2. pii: 10.1007/s00415-022-11197.
    PubMed     Abstract available


  218. ARINO H, Heartshorne R, Michael BD, Nicholson TR, et al
    Neuroimmune disorders in COVID-19.
    J Neurol. 2022;269:2827-2839.
    PubMed     Abstract available


  219. YOGANATHAN K, Stevenson A, Tahir A, Sadler R, et al
    Bedside and laboratory diagnostic testing in myasthenia.
    J Neurol. 2022;269:3372-3384.
    PubMed     Abstract available


  220. LAMBERT N, Lutteri L, Tshibanda L, Bianchi E, et al
    Anti-SOX1 antibody-associated acute hemorrhagic leukoencephalitis.
    J Neurol. 2022;269:3359-3362.
    PubMed    


  221. JENTZER A, Carra-Dalliere C, Lozano C, Riviere S, et al
    Neuromyelitis optica spectrum disorder following COVID-19 infection with increase in pre-existing anti-aquaporin-4 antibodies.
    J Neurol. 2022;269:2850-2853.
    PubMed    


  222. AYVACIOGLU CAGAN C, Temucin CM, Arslan D, Gocmen R, et al
    Isolated spinal cord granulomatous angiitis: a case report and review of the literature.
    J Neurol. 2022;269:3175-3179.
    PubMed     Abstract available


  223. VAN ROSMALEN MHJ, Froeling M, Mandija S, Hendrikse J, et al
    MRI of the intraspinal nerve roots in patients with chronic inflammatory neuropathies: abnormalities correlate with clinical phenotypes.
    J Neurol. 2022;269:3159-3166.
    PubMed     Abstract available


  224. ZIEMSSEN T, Lang M, Schmidt S, Albrecht H, et al
    Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.
    J Neurol. 2022;269:3276-3285.
    PubMed     Abstract available


  225. AKAISHI T, Misu T, Fujihara K, Takahashi T, et al
    Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
    J Neurol. 2022;269:3136-3146.
    PubMed     Abstract available


  226. DI SABATINO E, Gaetani L, Sperandei S, Fiacca A, et al
    The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI.
    J Neurol. 2022;269:3129-3135.
    PubMed     Abstract available


  227. MISCIOSCIA A, Puthenparampil M, Miante S, Pengo M, et al
    Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis.
    J Neurol. 2022 Jun 1. pii: 10.1007/s00415-022-11183.
    PubMed     Abstract available


    May 2022
  228. HRASTELJ J, Robertson NP
    A role for the Epstein-Barr virus in multiple sclerosis aetiology?
    J Neurol. 2022 May 31. pii: 10.1007/s00415-022-11177.
    PubMed    


  229. GOLD R, Piani-Meier D, Kappos L, Bar-Or A, et al
    Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
    J Neurol. 2022 May 31. pii: 10.1007/s00415-022-11166.
    PubMed     Abstract available


  230. JARIUS S, Komorowski L, Regula JU, Haas J, et al
    Rho GTPase-activating protein 10 (ARHGAP10/GRAF2) is a novel autoantibody target in patients with autoimmune encephalitis.
    J Neurol. 2022 May 27. pii: 10.1007/s00415-022-11178.
    PubMed     Abstract available


  231. WILLISON AG, Ruck T, Lenz G, Hartung HP, et al
    Correction to: The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
    J Neurol. 2022 May 24. pii: 10.1007/s00415-022-11158.
    PubMed    


  232. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
    Early use of high-efficacy diseasemodifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
    J Neurol. 2022 May 24. pii: 10.1007/s00415-022-11193.
    PubMed     Abstract available


  233. BATTAGLIA MA, Bezzini D, Cecchini I, Cordioli C, et al
    Patients with multiple sclerosis: a burden and cost of illness study.
    J Neurol. 2022 May 23. pii: 10.1007/s00415-022-11169.
    PubMed     Abstract available


  234. SOROSINA M, Barizzone N, Clarelli F, Anand S, et al
    A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.
    J Neurol. 2022 May 12. pii: 10.1007/s00415-022-11109.
    PubMed     Abstract available


  235. HONE L, Jacobs BM, Marshall C, Giovannoni G, et al
    Age-specific effects of childhood body mass index on multiple sclerosis risk.
    J Neurol. 2022 May 9. pii: 10.1007/s00415-022-11161.
    PubMed     Abstract available


  236. SPARASCI D, Gobbi C, Castelnovo A, Riccitelli GC, et al
    Fatigue, sleepiness and depression in multiple sclerosis: defining the overlaps for a better phenotyping.
    J Neurol. 2022 May 4. pii: 10.1007/s00415-022-11143.
    PubMed     Abstract available


  237. GIANNOCCARO MP, Vacchiano V, Leone M, Camilli F, et al
    Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study.
    J Neurol. 2022 May 3. pii: 10.1007/s00415-022-11142.
    PubMed     Abstract available


  238. SANSONE G, Bonifati DM
    Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients.
    J Neurol. 2022 May 3. pii: 10.1007/s00415-022-11140.
    PubMed     Abstract available


  239. KIM H, Fraser S
    Neural correlates of dual-task walking in people with central neurological disorders: a systematic review.
    J Neurol. 2022;269:2378-2402.
    PubMed     Abstract available


  240. GELIBTER S, Bellavia G, Arbasino C, Arno N, et al
    Encephalopathy as a prognostic factor in adults with acute disseminated encephalomyelitis following COVID-19.
    J Neurol. 2022;269:2293-2300.
    PubMed     Abstract available


  241. WEISS D, Cantre D, Zettl UK, Storch A, et al
    Lethal form of a late-onset aquaporin-4 antibody-positive NMOSD related to the immune checkpoint inhibitor nivolumab.
    J Neurol. 2022;269:2778-2780.
    PubMed    


  242. HIROSE S, Hara M, Kamei S, Dalmau J, et al
    Characteristics of clinical relapses and patient-oriented long-term outcomes of patients with anti-N-methyl-D-aspartate receptor encephalitis.
    J Neurol. 2022;269:2486-2492.
    PubMed     Abstract available


    April 2022
  243. HVID LG, Stenager E, Dalgas U
    Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study.
    J Neurol. 2022 Apr 28. pii: 10.1007/s00415-022-11134.
    PubMed     Abstract available


  244. EINSIEDLER M, Kremer L, Fleury M, Collongues N, et al
    Anti-CD20 immunotherapy in progressive multiple sclerosis: 2-year real-world follow-up of 108 patients.
    J Neurol. 2022 Apr 17. pii: 10.1007/s00415-022-11124.
    PubMed     Abstract available


  245. DUBBIOSO R, Bove M, Boccia D, D'Ambrosio V, et al
    Neurophysiological and behavioural correlates of ocrelizumab therapy on manual dexterity in patients with primary progressive multiple sclerosis.
    J Neurol. 2022 Apr 13. pii: 10.1007/s00415-022-11114.
    PubMed     Abstract available


  246. ZHANG Y, Yin H, Zhang D, Xu Y, et al
    Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
    J Neurol. 2022 Apr 11. pii: 10.1007/s00415-022-11118.
    PubMed     Abstract available


  247. WILLISON AG, Ruck T, Lenz G, Hartung HP, et al
    The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
    J Neurol. 2022 Apr 11. pii: 10.1007/s00415-022-11063.
    PubMed     Abstract available


  248. STORELLI L, Pagani E, Meani A, Preziosa P, et al
    Advanced diffusion-weighted imaging models better characterize white matter neurodegeneration and clinical outcomes in multiple sclerosis.
    J Neurol. 2022 Apr 10. pii: 10.1007/s00415-022-11104.
    PubMed     Abstract available


  249. CAROLUS K, Fuchs TA, Bergsland N, Ramasamy D, et al
    Time course of lesion-induced atrophy in multiple sclerosis.
    J Neurol. 2022 Apr 8. pii: 10.1007/s00415-022-11094.
    PubMed     Abstract available


  250. MOOG TM, McCreary M, Wilson A, Stanley T, et al
    Direction and magnitude of displacement differ between slowly expanding and non-expanding multiple sclerosis lesions as compared to small vessel disease.
    J Neurol. 2022 Apr 5. pii: 10.1007/s00415-022-11089.
    PubMed     Abstract available


  251. BUONOMO AR, Viceconte G, Calabrese M, De Luca G, et al
    Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
    J Neurol. 2022 Apr 4. pii: 10.1007/s00415-022-11066.
    PubMed    


  252. VANDEBERGH M, Degryse N, Dubois B, Goris A, et al
    Environmental risk factors in multiple sclerosis: bridging Mendelian randomization and observational studies.
    J Neurol. 2022 Apr 2. pii: 10.1007/s00415-022-11072.
    PubMed     Abstract available


  253. FEINSTEIN A, Amato MP, Brichetto G, Chataway J, et al
    The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience.
    J Neurol. 2022;269:1758-1763.
    PubMed     Abstract available


  254. ROJAS JI, Pappolla A, Blaya P, Marrodan M, et al
    Accumulative risk of clinical event in high-risk radiologically isolated syndrome in Argentina: data from the nationwide registry RelevarEM.
    J Neurol. 2022;269:2073-2079.
    PubMed     Abstract available


  255. ABBOUD H, Salazar-Camelo A, George N, Planchon SM, et al
    Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders.
    J Neurol. 2022;269:1786-1801.
    PubMed     Abstract available


  256. MASUDA H, Mori M, Yokouchi H, Uzawa A, et al
    Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders.
    J Neurol. 2022;269:1996-2003.
    PubMed     Abstract available


    March 2022
  257. DEANA C, Bagatto D, Battezzi A, Pecori D, et al
    Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report.
    J Neurol. 2022 Mar 30. pii: 10.1007/s00415-022-11097.
    PubMed    


  258. BISECCO A, Fornasiero A, Bianco A, Cortese A, et al
    Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.
    J Neurol. 2022 Mar 27. pii: 10.1007/s00415-022-11083.
    PubMed    


  259. WENZEL N, Wittayer M, Weber CE, Schirmer L, et al
    MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions.
    J Neurol. 2022 Mar 25. pii: 10.1007/s00415-022-11082.
    PubMed     Abstract available


  260. ALLMAN M, Tallantyre E, Robertson NP
    Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies.
    J Neurol. 2022 Mar 14. pii: 10.1007/s00415-022-11053.
    PubMed    


  261. MISTRI D, Cacciaguerra L, Storelli L, Meani A, et al
    The association between cognition and motor performance is beyond structural damage in relapsing-remitting multiple sclerosis.
    J Neurol. 2022 Mar 12. pii: 10.1007/s00415-022-11044.
    PubMed     Abstract available


  262. DU Y, Li C, Hao YF, Zhao C, et al
    Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.
    J Neurol. 2022 Mar 3. pii: 10.1007/s00415-022-11048.
    PubMed     Abstract available


  263. MARIOTTINI A, Bertozzi A, Marchi L, Di Cristinzi M, et al
    Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis.
    J Neurol. 2022 Mar 3. pii: 10.1007/s00415-022-11003.
    PubMed     Abstract available


  264. ACHIRON A, Mandel M, Gurevich M, Dreyer-Alster S, et al
    Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
    J Neurol. 2022 Mar 2. pii: 10.1007/s00415-022-11030.
    PubMed     Abstract available


  265. KUBICKI K, Grzybowski A
    Pioneers in neurology: Charles Miller Fisher (1913-2012).
    J Neurol. 2022;269:1727-1729.
    PubMed    


  266. KANINIA S, Edey AJ, Maskell NA, Rice CM, et al
    Natalizumab-induced pneumonitis.
    J Neurol. 2022;269:1688-1690.
    PubMed    


  267. KHAN E, Shrestha AK, Colantonio MA, Liberio RN, et al
    Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature.
    J Neurol. 2022;269:1121-1132.
    PubMed     Abstract available


  268. WANG Y, Wang Y, Huo L, Li Q, et al
    SARS-CoV-2-associated acute disseminated encephalomyelitis: a systematic review of the literature.
    J Neurol. 2022;269:1071-1092.
    PubMed     Abstract available


  269. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset.
    J Neurol. 2022;269:1663-1669.
    PubMed     Abstract available


  270. XIE H, Shao Y, Du J, Song Y, et al
    Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.
    J Neurol. 2022;269:1641-1650.
    PubMed     Abstract available


  271. NISSEN MS, Orvik MS, Nilsson AC, Ryding M, et al
    NMDA-receptor encephalitis in Denmark from 2009 to 2019: a national cohort study.
    J Neurol. 2022;269:1618-1630.
    PubMed     Abstract available


  272. CACCIAGUERRA L, Storelli L, Radaelli M, Mesaros S, et al
    Application of deep-learning to the seronegative side of the NMO spectrum.
    J Neurol. 2022;269:1546-1556.
    PubMed     Abstract available


  273. HU J, Sun C, Lu J, Zhao C, et al
    Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.
    J Neurol. 2022;269:1250-1263.
    PubMed     Abstract available


  274. BONACCHI R, Meani A, Pagani E, Marchesi O, et al
    The role of cerebellar damage in explaining disability and cognition in multiple sclerosis phenotypes: a multiparametric MRI study.
    J Neurol. 2022 Mar 1. pii: 10.1007/s00415-022-11021.
    PubMed     Abstract available


    February 2022
  275. COBO-CALVO A, Zabalza A, Rio J, Arrambide G, et al
    Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.
    J Neurol. 2022 Feb 22. pii: 10.1007/s00415-022-11019.
    PubMed    


  276. BERG-HANSEN P, Moen SM, Austeng A, Gonzales V, et al
    Sensor-based gait analyses of the six-minute walk test identify qualitative improvement in gait parameters of people with multiple sclerosis after rehabilitation.
    J Neurol. 2022 Feb 15. pii: 10.1007/s00415-022-10998.
    PubMed     Abstract available


  277. RICCARDO BA, Giulio V, Massimiliano C, Giovanna L, et al
    Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
    J Neurol. 2022 Feb 14. pii: 10.1007/s00415-022-11009.
    PubMed     Abstract available


  278. CHIARAVALLOTI ND, Costa SL, Moore NB, Costanza K, et al
    The efficacy of speed of processing training for improving processing speed in individuals with multiple sclerosis: a randomized clinical trial.
    J Neurol. 2022 Feb 12. pii: 10.1007/s00415-022-10980.
    PubMed     Abstract available


  279. SOULAGES A, Sibon I, Vallat JM, Ellie E, et al
    Neurologic manifestations of giant cell arteritis.
    J Neurol. 2022 Feb 6. pii: 10.1007/s00415-022-10991.
    PubMed     Abstract available


  280. ALCALA C, Quintanilla-Bordas C, Gascon F, Sempere AP, et al
    Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
    J Neurol. 2022 Feb 2. pii: 10.1007/s00415-022-10989.
    PubMed     Abstract available


  281. ISMAIL II, Salama S
    Association of CNS demyelination and COVID-19 infection: an updated systematic review.
    J Neurol. 2022;269:541-576.
    PubMed     Abstract available


  282. PATZIG M, Forbrig R, Kupper C, Eren O, et al
    Diagnosis and follow-up evaluation of central nervous system vasculitis: an evaluation of vessel-wall MRI findings.
    J Neurol. 2022;269:982-996.
    PubMed     Abstract available


  283. BUKHARI W, Khalilidehkordi E, Mason DF, Barnett MH, et al
    NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand.
    J Neurol. 2022;269:836-845.
    PubMed     Abstract available


  284. SPINA E, Doneddu PE, Liberatore G, Cocito D, et al
    Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP.
    J Neurol. 2022;269:907-912.
    PubMed     Abstract available


  285. BUS SRM, Broers MC, Lucke IM, Bunschoten C, et al
    Clinical outcome of CIDP one year after start of treatment: a prospective cohort study.
    J Neurol. 2022;269:945-955.
    PubMed     Abstract available


  286. LANDI D, Signori A, Cellerino M, Fenu G, et al
    What happens after fingolimod discontinuation? A multicentre real-life experience.
    J Neurol. 2022;269:796-804.
    PubMed     Abstract available


    January 2022
  287. VIRGILIO E, Vecchio D, Crespi I, Puricelli C, et al
    Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis.
    J Neurol. 2022 Jan 28. pii: 10.1007/s00415-021-10945.
    PubMed     Abstract available


  288. PROSCHINGER S, Kuhwand P, Rademacher A, Walzik D, et al
    Fitness, physical activity, and exercise in multiple sclerosis: a systematic review on current evidence for interactions with disease activity and progression.
    J Neurol. 2022 Jan 27. pii: 10.1007/s00415-021-10935.
    PubMed     Abstract available


  289. GADOTH A, Segal Y, Paran Y, Aizenstein O, et al
    The importance of tissue-based assay in the diagnosis of autoimmune encephalitis.
    J Neurol. 2022 Jan 25. pii: 10.1007/s00415-022-10973.
    PubMed     Abstract available


  290. PAPADOPOULOS D, Gklinos P, Psarros G, Drellia K, et al
    Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression.
    J Neurol. 2022 Jan 23. pii: 10.1007/s00415-021-10932.
    PubMed     Abstract available


  291. BERGAMASCHI R, Mallucci G, Fusco S, Montomoli C, et al
    Disability and mortality in a cohort of MS patients: how the real-world scenario is changed.
    J Neurol. 2022 Jan 14. pii: 10.1007/s00415-021-10940.
    PubMed    


  292. MORANO A, Cerulli Irelli E, Fanella M, Orlando B, et al
    Olfactory impairment in autoimmune encephalitis: another piece of the puzzle.
    J Neurol. 2022 Jan 10. pii: 10.1007/s00415-022-10959.
    PubMed     Abstract available


  293. COBO-CALVO A, Zabalza A, Rio J, Arrambide G, et al
    Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.
    J Neurol. 2022 Jan 10. pii: 10.1007/s00415-021-10958.
    PubMed     Abstract available


  294. CRUZ RA, Varkey T, Flavia A, Samways APA, et al
    Hearing abnormalities in multiple sclerosis: clinical semiology and pathophysiologic mechanisms.
    J Neurol. 2022 Jan 9. pii: 10.1007/s00415-021-10915.
    PubMed     Abstract available


  295. KORSEN M, Pfeuffer S, Rolfes L, Meuth SG, et al
    Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.
    J Neurol. 2022 Jan 9. pii: 10.1007/s00415-021-10956.
    PubMed     Abstract available


  296. PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
    Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies.
    J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10951.
    PubMed     Abstract available


  297. BIGAUT K, Kremer L, Fabacher T, Ahle G, et al
    Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
    J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10950.
    PubMed     Abstract available


  298. THOMAS R, Wynford-Thomas R, Robertson NP
    Advances in the use of stem cell transplants in the treatment of multiple sclerosis.
    J Neurol. 2022 Jan 4. pii: 10.1007/s00415-021-10927.
    PubMed    


  299. TALAEI M, Robertson NP
    Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy.
    J Neurol. 2022;269:534-536.
    PubMed    


  300. ZRZAVY T, Wielandner A, Haider L, Bartsch S, et al
    FLAIR(2) post-processing: improving MS lesion detection in standard MS imaging protocols.
    J Neurol. 2022;269:461-467.
    PubMed     Abstract available


  301. XU J, Guo Y, Li J, Lv X, et al
    Progressive cortical and sub-cortical alterations in patients with anti-N-methyl-D-aspartate receptor encephalitis.
    J Neurol. 2022;269:389-398.
    PubMed     Abstract available


  302. HELMCHEN C, Buttler GM, Markewitz R, Hummel K, et al
    Acute bilateral optic/chiasm neuritis with longitudinal extensive transverse myelitis in longstanding stable multiple sclerosis following vector-based vaccination against the SARS-CoV-2.
    J Neurol. 2022;269:49-54.
    PubMed    


  303. DE LOTT LB, Bennett JL, Costello F
    The changing landscape of optic neuritis: a narrative review.
    J Neurol. 2022;269:111-124.
    PubMed     Abstract available


    December 2021
  304. LEGUY S, Le Page E, Drapier S
    Elderly onset neuromyelitis optica spectrum disorder: a case report.
    J Neurol. 2021;268:4897-4898.
    PubMed    


  305. SRIWASTAVA S, Tandon M, Podury S, Prasad A, et al
    COVID-19 and neuroinflammation: a literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from SARS-COV2.
    J Neurol. 2021;268:4448-4478.
    PubMed     Abstract available


  306. KONIG N, Stetefeld HR, Dohmen C, Mergenthaler P, et al
    MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation.
    J Neurol. 2021;268:4824-4833.
    PubMed     Abstract available


  307. FLANAGAN EP
    Paraneoplastic disorders of the nervous system.
    J Neurol. 2021;268:4899-4907.
    PubMed     Abstract available


  308. CABAL-HERRERA AM, Mateen FJ
    COVID-19 in a patient treated with eculizumab for aquaporin-4 neuromyelitis optica.
    J Neurol. 2021;268:4479-4482.
    PubMed    


  309. SIRITHO S, Nopsopon T, Pongpirul K
    Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis.
    J Neurol. 2021;268:4549-4562.
    PubMed     Abstract available


  310. HOLMOY T, Hoglund RA, Illes Z, Myhr KM, et al
    Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.
    J Neurol. 2021;268:4522-4536.
    PubMed     Abstract available


    November 2021
  311. KAMBADJA B, Marion H, Cousyn L, Mezouar N, et al
    When should we test patients with epilepsy for autoimmune antibodies? Results from a French retrospective single center study.
    J Neurol. 2021 Nov 23. pii: 10.1007/s00415-021-10894.
    PubMed     Abstract available


  312. ANDERSEN LK, Jakobsson AS, Revsbech KL, Vissing J, et al
    Causes of symptom dissatisfaction in patients with generalized myasthenia gravis.
    J Neurol. 2021 Nov 21. pii: 10.1007/s00415-021-10902.
    PubMed     Abstract available


  313. RIO J, Rovira A, Gasperini C, Tintore M, et al
    Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10906.
    PubMed    


  314. LAUVSNES MB, Zetterberg H, Blennow K, Kvaloy JT, et al
    Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10893.
    PubMed     Abstract available


  315. SRIWASTAVA S, Chaudhary D, Srivastava S, Beard K, et al
    Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10910.
    PubMed     Abstract available


  316. LEHNERER S, Jacobi J, Schilling R, Grittner U, et al
    Burden of disease in myasthenia gravis: taking the patient's perspective.
    J Neurol. 2021 Nov 20. pii: 10.1007/s00415-021-10891.
    PubMed     Abstract available


  317. CHAMBERLAIN JL, Huda S, Whittam DH, Matiello M, et al
    Correction to: Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.
    J Neurol. 2021 Nov 15. pii: 10.1007/s00415-021-10896.
    PubMed    


  318. MCHATTIE AW, Coebergh J, Khan F, Morgante F, et al
    Palilalia as a prominent feature of anti-NMDA receptor encephalitis in a woman with COVID-19.
    J Neurol. 2021;268:3995-3997.
    PubMed    


    October 2021
  319. FUCHS TA, Schoonheim MM, Broeders TAA, Hulst HE, et al
    Functional network dynamics and decreased conscientiousness in multiple sclerosis.
    J Neurol. 2021 Oct 29. pii: 10.1007/s00415-021-10860.
    PubMed     Abstract available


  320. WASHINGTON F, Langdon D
    Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review.
    J Neurol. 2021 Oct 21. pii: 10.1007/s00415-021-10850.
    PubMed     Abstract available


  321. ALSCHULER KN, Whibley D, Kratz AL, Jensen MP, et al
    Quality of life in individuals newly diagnosed with multiple sclerosis or clinically isolated syndrome.
    J Neurol. 2021 Oct 19. pii: 10.1007/s00415-021-10842.
    PubMed     Abstract available


  322. BURT RK, Han X, Quigley K, Helenowski IB, et al
    Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis.
    J Neurol. 2021 Oct 11. pii: 10.1007/s00415-021-10820.
    PubMed     Abstract available


  323. FILIPPI M, Danesi R, Derfuss T, Duddy M, et al
    Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis.
    J Neurol. 2021 Oct 9. pii: 10.1007/s00415-021-10836.
    PubMed     Abstract available


  324. PREZIOSA P, Conti L, Rocca MA, Filippi M, et al
    Effects on cognition of DMTs in multiple sclerosis: moving beyond the prevention of inflammatory activity.
    J Neurol. 2021 Oct 7. pii: 10.1007/s00415-021-10832.
    PubMed     Abstract available


  325. AL-ANSARI A, Robertson NP
    Autoimmune encephalitis: clinical presentation, investigation and treatment.
    J Neurol. 2021;268:3935-3937.
    PubMed    


  326. FUKAMI Y, Iijima M, Koike H, Yamada S, et al
    Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients.
    J Neurol. 2021;268:3835-3844.
    PubMed     Abstract available


  327. JARIUS S, Wilken D, Haas J, Ruprecht K, et al
    Parvovirus B19 and mumps virus antibodies are major constituents of the intrathecal immune response in European patients with MS and increase the diagnostic sensitivity and discriminatory power of the MRZ reaction.
    J Neurol. 2021;268:3758-3765.
    PubMed     Abstract available


  328. QUEROL L, Crabtree M, Herepath M, Priedane E, et al
    Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP).
    J Neurol. 2021;268:3706-3716.
    PubMed     Abstract available


  329. RIO J, Rovira A, Gasperini C, Tintore M, et al
    Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients.
    J Neurol. 2021 Oct 1. pii: 10.1007/s00415-021-10823.
    PubMed     Abstract available


    September 2021
  330. AHMED A, Kok ZQ, Coles A, Scoffings DJ, et al
    Susac's syndrome as an autoimmune complication of alemtuzumab-associated immune reconstitution.
    J Neurol. 2021 Sep 29. pii: 10.1007/s00415-021-10802.
    PubMed    


  331. PUTHENPARAMPIL M, Perini P, Bergamaschi R, Capobianco M, et al
    Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors.
    J Neurol. 2021 Sep 27. pii: 10.1007/s00415-021-10782.
    PubMed     Abstract available


  332. PROSPERINI L, Tortorella C, Haggiag S, Ruggieri S, et al
    Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies.
    J Neurol. 2021 Sep 17. pii: 10.1007/s00415-021-10803.
    PubMed     Abstract available


  333. BOZOVIC I, Ilic Zivojinovic J, Peric S, Kostic M, et al
    Long-term outcome in patients with myasthenia gravis: one decade longitudinal study.
    J Neurol. 2021 Sep 4. pii: 10.1007/s00415-021-10759.
    PubMed     Abstract available


  334. BERCIANO J
    Pathogenic events in very early Guillain-Barre syndrome: neither demyelination nor axonal degeneration but endoneurial inflammatory oedema.
    J Neurol. 2021 Sep 3. pii: 10.1007/s00415-021-10773.
    PubMed    


  335. ANDERSEN MA, Buron MD, Magyari M
    Late-onset MS is associated with an increased rate of reaching disability milestones.
    J Neurol. 2021;268:3352-3360.
    PubMed     Abstract available


  336. HOFSTADT-VAN OY U, Stankovic S, Kelbel C, Oswald D, et al
    Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19.
    J Neurol. 2021;268:3125-3128.
    PubMed     Abstract available


  337. VAN LOOY E, Veenker L, Steyaert A, Leenders J, et al
    COVID-19-induced exacerbation of chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2021;268:3129-3131.
    PubMed    


    August 2021
  338. SUN J, Xie Y, Wang Q, Shen J, et al
    Genes associated with grey matter volume reduction in multiple sclerosis.
    J Neurol. 2021 Aug 29. pii: 10.1007/s00415-021-10777.
    PubMed     Abstract available


  339. BLOCK VJ, Pitsch EA, Gopal A, Zhao C, et al
    Identifying falls remotely in people with multiple sclerosis.
    J Neurol. 2021 Aug 17. pii: 10.1007/s00415-021-10743.
    PubMed     Abstract available


  340. MARGONI M, Preziosa P, Filippi M, Rocca MA, et al
    Anti-CD20 therapies for multiple sclerosis: current status and future perspectives.
    J Neurol. 2021 Aug 11. pii: 10.1007/s00415-021-10744.
    PubMed     Abstract available


  341. ALVINO B, Arianna F, Assunta B, Antonio C, et al
    Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study.
    J Neurol. 2021 Aug 4. pii: 10.1007/s00415-021-10737.
    PubMed     Abstract available


  342. PARDO G, Coates S, Okuda DT
    Outcome measures assisting treatment optimization in multiple sclerosis.
    J Neurol. 2021 Aug 2. pii: 10.1007/s00415-021-10674.
    PubMed     Abstract available


  343. FIONDA L, Di Pasquale A, Morino S, Leonardi L, et al
    Changes of clinical, neurophysiological and nerve ultrasound characteristics in CIDP over time: a 3-year follow-up.
    J Neurol. 2021;268:3011-3019.
    PubMed     Abstract available


  344. CORTESE R, Prosperini L, Stasolla A, Haggiag S, et al
    Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy.
    J Neurol. 2021;268:2895-2899.
    PubMed     Abstract available


  345. CILINGIR V, Batur M
    First measured retinal nerve fiber layer thickness in RRMS can be used as a biomarker for the course of the disease: threshold value discussions.
    J Neurol. 2021;268:2858-2865.
    PubMed     Abstract available


  346. WANSCHITZ JV, Kaml M, Pfausler B, Helbok R, et al
    Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up.
    J Neurol. 2021;268:2700-2702.
    PubMed    


    July 2021
  347. O SULLIVAN C, Zach F, Moser T, Pilz G, et al
    Misinterpretation of glioblastoma as ADEM: potentially harmful consequences of over-diagnosis of COVID-19 vaccine-associated adverse events.
    J Neurol. 2021 Jul 24. pii: 10.1007/s00415-021-10707.
    PubMed    


  348. FERRARO D, Iaffaldano P, Guerra T, Inglese M, et al
    Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.
    J Neurol. 2021 Jul 22. pii: 10.1007/s00415-021-10708.
    PubMed     Abstract available


  349. RAUMA I, Mustonen T, Seppa JM, Ukkonen M, et al
    Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients.
    J Neurol. 2021 Jul 13. pii: 10.1007/s00415-021-10664.
    PubMed     Abstract available


  350. NIESSEN A, Schwarz B, Urban M, Kramer S, et al
    Aseptic meningitis after glatiramer acetate.
    J Neurol. 2021;268:2589-2590.
    PubMed    


  351. STARMANS NLP, van Dijk MR, Kappelle LJ, Frijns CJM, et al
    Sneddon syndrome: a comprehensive clinical review of 53 patients.
    J Neurol. 2021;268:2450-2457.
    PubMed     Abstract available


  352. MASUCCIO FG, Barra M, Claudio G, Claudio S, et al
    A rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection.
    J Neurol. 2021;268:2327-2330.
    PubMed     Abstract available


    June 2021
  353. CHISARI CG, Comi G, Filippi M, Paolicelli D, et al
    PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10676.
    PubMed     Abstract available


  354. SANKARI SE, Van Essche C, van Pesch V
    Cutaneous diseases related to a hyperactive T-cell response in ocrelizumab-treated multiple sclerosis patients.
    J Neurol. 2021 Jun 28. pii: 10.1007/s00415-021-10679.
    PubMed    


  355. KOGEL AK, Gold R, Schneider R
    CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
    J Neurol. 2021 Jun 27. pii: 10.1007/s00415-021-10661.
    PubMed    


  356. S G, S L, C Z, A N, et al
    Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.
    J Neurol. 2021 Jun 26. pii: 10.1007/s00415-021-10663.
    PubMed     Abstract available


  357. HANNINEN K, Viitala M, Atula S, Laakso SM, et al
    Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study.
    J Neurol. 2021 Jun 25. pii: 10.1007/s00415-021-10673.
    PubMed     Abstract available


  358. HAVLA J, Schultz Y, Zimmermann H, Hohlfeld R, et al
    First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.
    J Neurol. 2021 Jun 11. pii: 10.1007/s00415-021-10648.
    PubMed    


  359. KIM SH, Baek SH, Lee SU, Yu S, et al
    Optic disc edema as a sole manifestation of anti-GQ1b antibody syndrome.
    J Neurol. 2021;268:2263-2266.
    PubMed    


  360. DAO LM, Machule ML, Bacher P, Hoffmann J, et al
    Decreased inflammatory cytokine production of antigen-specific CD4(+) T cells in NMDA receptor encephalitis.
    J Neurol. 2021;268:2123-2131.
    PubMed     Abstract available


  361. LLORENTE AYUSO L, Torres Rubio P, Beijinho do Rosario RF, Giganto Arroyo ML, et al
    Bickerstaff encephalitis after COVID-19.
    J Neurol. 2021;268:2035-2037.
    PubMed    


    May 2021
  362. JURYNCZYK M, Klimiec-Moskal E, Kong Y, Hurley S, et al
    Elucidating distinct clinico-radiologic signatures in the borderland between neuromyelitis optica and multiple sclerosis.
    J Neurol. 2021 May 27. pii: 10.1007/s00415-021-10619.
    PubMed     Abstract available


  363. CHEN MH, Chiaravalloti ND, DeLuca J
    Neurological update: cognitive rehabilitation in multiple sclerosis.
    J Neurol. 2021 May 24. pii: 10.1007/s00415-021-10618.
    PubMed     Abstract available


  364. HOU Y, Shao K, Yan Y, Dai T, et al
    Anti-HMGCR myopathy overlaps with dermatomyositis-like rash: a distinct subtype of idiopathic inflammatory myopathy.
    J Neurol. 2021 May 21. pii: 10.1007/s00415-021-10621.
    PubMed     Abstract available


  365. KILIC MA, Yoruk Yildirim ZN, Oner A, Yesil E, et al
    Pediatric LGI1 and CASPR2 autoimmunity associated with COVID 19: Morvan syndrome.
    J Neurol. 2021 May 18. pii: 10.1007/s00415-021-10614.
    PubMed    


  366. ZRZAVY T, Pfitzner A, Flachenecker P, Rommer P, et al
    Effects of normobaric hypoxic endurance training on fatigue in patients with multiple sclerosis: a randomized prospective pilot study.
    J Neurol. 2021 May 18. pii: 10.1007/s00415-021-10596.
    PubMed     Abstract available


  367. HILDESHEIM FE, Benedict RHB, Zivadinov R, Dwyer MG, et al
    Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis.
    J Neurol. 2021 May 16. pii: 10.1007/s00415-021-10594.
    PubMed     Abstract available


  368. TOMMASIN S, Cocozza S, Taloni A, Gianni C, et al
    Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis.
    J Neurol. 2021 May 10. pii: 10.1007/s00415-021-10605.
    PubMed     Abstract available


  369. RUGGIERI S, Petracca M, De Giglio L, De Luca F, et al
    A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis.
    J Neurol. 2021 May 3. pii: 10.1007/s00415-021-10576.
    PubMed     Abstract available


  370. THOUIN A, Gastaldi M, Woodhall M, Jacobson L, et al
    Comparison of N-methyl-D-aspartate receptor antibody assays using live or fixed substrates.
    J Neurol. 2021;268:1818-1826.
    PubMed     Abstract available


    April 2021
  371. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    J Neurol. 2021 Apr 22. pii: 10.1007/s00415-021-10559.
    PubMed     Abstract available


  372. COVEY TJ, Golan D, Doniger GM, Sergott R, et al
    Visual evoked potential latency predicts cognitive function in people with multiple sclerosis.
    J Neurol. 2021 Apr 18. pii: 10.1007/s00415-021-10561.
    PubMed     Abstract available


  373. CENTONZE D, Rocca MA, Gasperini C, Kappos L, et al
    Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
    J Neurol. 2021 Apr 12. pii: 10.1007/s00415-021-10545.
    PubMed     Abstract available


  374. WILF-YARKONI A, Lotan I, Steiner I, Hellmann MA, et al
    Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis.
    J Neurol. 2021 Apr 7. pii: 10.1007/s00415-021-10544.
    PubMed     Abstract available


  375. NYGAARD MKE, Langeskov-Christensen M, Dalgas U, Eskildsen SF, et al
    Cortical diffusion kurtosis imaging and thalamic volume are associated with cognitive and walking performance in relapsing-remitting multiple sclerosis.
    J Neurol. 2021 Apr 7. pii: 10.1007/s00415-021-10543.
    PubMed     Abstract available


  376. URBAIN F, Puyade M, Labeyrie C, Maubeuge N, et al
    Hematopoietic stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: French experience about four patients, under the behalf of French society for bone marrow transplantation.
    J Neurol. 2021;268:1536-1539.
    PubMed    


  377. KAPOOR M, Keh R, Compton L, Morrow S, et al
    Subcutaneous immunoglobulin dose titration to clinical response in inflammatory neuropathy.
    J Neurol. 2021;268:1485-1490.
    PubMed     Abstract available


  378. NETRAVATHI M, Holla VV, Nalini A, Yadav R, et al
    Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder.
    J Neurol. 2021;268:1419-1433.
    PubMed     Abstract available


  379. CHAUDHARY UJ, Rajabally YA
    Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2021;268:1366-1373.
    PubMed     Abstract available


    March 2021
  380. VAN ROSMALEN MHJ, Goedee HS, van der Gijp A, Witkamp TD, et al
    Quantitative assessment of brachial plexus MRI for the diagnosis of chronic inflammatory neuropathies.
    J Neurol. 2021;268:978-988.
    PubMed     Abstract available


  381. MATHIS S, Soulages A, Le Masson G, Vallat JM, et al
    Epidemics and outbreaks of peripheral nervous system disorders: I. infectious and immune-mediated causes.
    J Neurol. 2021;268:879-890.
    PubMed     Abstract available


    February 2021
  382. YOO JS, Kim YS, Kim HY, Kwon HS, et al
    Comparison of patients with transient and sustained increments of antiphospholipid antibodies after acute ischemic stroke.
    J Neurol. 2021 Feb 6. pii: 10.1007/s00415-021-10432.
    PubMed     Abstract available


  383. MARTIN T, Duke S, Kumar V, Fadhil A, et al
    NMDAR antibody encephalitis overlapping with CLIPPERS syndrome in a psoriasis patient on adalimumab.
    J Neurol. 2021;268:714-716.
    PubMed    


  384. SCHROTER N, Weiller C, Rauer S, Waller CF, et al
    Anti-glycin-receptor antibody related stiff-person syndrome under treatment with an immune checkpoint inhibitor.
    J Neurol. 2021;268:709-711.
    PubMed    


  385. OKADA K, Seki M, Yaguchi H, Sakuta K, et al
    Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature.
    J Neurol. 2021;268:680-688.
    PubMed     Abstract available


  386. BERGMAN J, Burman J, Bergenheim T, Svenningsson A, et al
    Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.
    J Neurol. 2021;268:651-657.
    PubMed     Abstract available


    January 2021
  387. STOECKLEIN VM, Kellert L, Patzig M, Kupper C, et al
    Extended stereotactic brain biopsy in suspected primary central nervous system angiitis: good diagnostic accuracy and high safety.
    J Neurol. 2021;268:367-376.
    PubMed     Abstract available


  388. KASS-ILIYYA L, Snowden JA, Thorpe A, Jessop H, et al
    Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience.
    J Neurol. 2021;268:265-275.
    PubMed     Abstract available


    July 2020
  389. BIEN CG, Bien CI, Dogan Onugoren M, De Simoni D, et al
    Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome.
    J Neurol. 2020;267:2101-2114.
    PubMed     Abstract available


  390. MUNIZ-CASTRILLO S, Ambati A, Dubois V, Vogrig A, et al
    Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies.
    J Neurol. 2020;267:1906-1911.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.